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NELL-1, HMGB1, and CCN2 Enhance Migration
and Vasculogenesis, But Not Osteogenic
Differentiation Compared to BMP2
Shorouk Fahmy-Garcia, MSc,1 Marjolein van Driel, PhD,2 Janneke Witte-Buoma, BSc,3 Heike Walles, PhD,4
Johannes P.T.M. van Leeuwen, PhD,2 Gerjo J.V.M van Osch, PhD,1,5 and Eric Farrell, PhD3
Currently, autografts still represent the gold standard treatment for the repair of large bone defects. However,
these are associated with donor-site morbidity and increased pain, cost, and recovery time. The ideal therapy
would use biomaterials combined with bone growth factors to induce and instruct bone defect repair without the
need to harvest patient tissue. In this line, bone morphogenetic proteins (BMPs) have been the most extensively
used agents for clinical bone repair, but at supraphysiological doses that are not without risk. Because of the
need to eliminate the risks of BMP2 use in vivo, we assessed the ability of three putative osteogenic factors, nel-
like molecule type 1 (NELL-1), high mobility group box 1 (HMGB1), and CCN2, to enhance the essential
processes for bone defect repair in vitro and compared them to BMP2. Although it has been reported that
NELL-1, HMGB1, and CCN2 play a role in bone formation, less is known about the contribution of these
proteins to the different events involved, such as cell migration, osteogenesis, and vasculogenesis. In this study,
we investigated the effects of different doses of NELL-1, HMGB, CCN2, and BMP2 on these three processes as
a model for the recruitment and differentiation of resident cells in the in vivo bone defect repair situation, using
cells of human origin. Our data demonstrated that NELL-1, HMGB1, and CCN2 significantly induced mes-
enchymal stem cell migration (from 1.58-fold increase compared to control), but BMP2 did not. Interestingly,
only BMP2 increased osteogenesis in marrow stromal cells, whereas it inhibited osteogenesis in preosteoblasts.
Moreover, the four proteins studied promoted significantly endothelial cell migration, reaching a maximum of
2.4-fold increase compared to control, and induced formation of tube-like structures. NELL-1, HMGB1, and
CCN2 had these effects at relatively low doses compared to BMP2. This work indicates that NELL-1, HMGB1,
and CCN2 might enhance bone defect healing via the recruitment of endogenous cells and induction of
vascularization and act via different processes than BMP2.
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Introduction
Currently, bone grafting is used to replace missingbone and to repair bone fractures, with 2.2 million
transplantations per year.1 Autografts represent the gold
standard due to their histocompatibility and capacity to
become vascularized and fully integrated with the sur-
rounding bone. Although autografts have an excellent suc-
cess rate, the harvesting of autologous bone is associated
with an 8.6% rate of major and 20.6% minor complications.2
Therefore, different approaches are being taken to overcome
these limitations. The ideal regenerative medicine approach
would involve an off-the-shelf product that can recruit a
patient’s own cells and stimulate them to differentiate into
mature osteoblasts while at the same time inducing tissue
vascularization. One such approach is growth factor-based
therapy. This involves the use of molecules that are essential
for tissue formation combined with biomaterials.3
Bone morphogenetic protein 2 (BMP2) and BMP7 are the
most studied bone forming proteins. Moreover, currently
BMP2 is the only BMP approved as a bone graft substitute.4
However, despite the therapeutic potential of BMP2 in bone
repair, large doses (up to 40mg) are needed to produce a
significant osteogenic effect,5 and this can result in undesired
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ectopic bone formation, soft tissue swelling, bone resorp-
tion, and tumor growth enhancement through angiogenesis
stimulation.6–8
Accordingly, alternative proteins are being assessed for
their osteogenic induction capacity. Three of such proteins
are nel-like molecule type 1 (NELL-1), connective tissue
growth factor (also known as CCN2), and high mobility
group box 1 (HMGB1). Bone regeneration is a complex
process that involves a series of well-orchestrated biological
events. At the cellular level, migration, proliferation, an-
giogenesis, osteogenic differentiation, and subsequent min-
eralization are essential processes to enable bone formation
and repair to occur.9 To optimize in vivo bone defect repair
using biologicals, more knowledge of the effect of these
factors on the different processes is necessary.
NELL-1 is a secretory protein and its overexpression in-
duces altered bone formation and it is considered an essential
factor for human craniosynostosis.10 It has been shown to
promote bone formation on mice in vivo,11,12 and in a com-
parison study, NELL-1-based bone grafts were comparable to
BMP2-based grafts in rat spinal fusion.13 Recent studies
performed on osteoporotic mice and sheep have shown that
NELL-1 could potentially be used as a therapy for osteopo-
rotic bone loss.14,15 Furthermore, NELL-1 has been shown to
increase osteogenic differentiation in vitro.16 However,
whether NELL-1 is able to recruit osteoprogenitor cells is not
known yet. Moreover, several genes affected by NELL-1
appear to promote angiogenesis at early stages of bone re-
generation,17 but whether it is able to promote endothelial cell
(EC) recruitment and differentiation is still unknown.
CCN2 has been used mostly in rats and has been shown to
promote bone and cartilage regeneration.18,19 It is one of the
six CCN matricellular proteins characterized by their con-
served modular structure20 and interacts with integrins, en-
hancing cellular processes such as adhesion, extracellular
matrix (ECM) synthesis, cytoskeleton reorganization, and
survival.21–23 In vitro studies have shown that overexpressing
cells with CCN2 promote mesenchymal cell proliferation,
migration, and aggregation.24,25 In addition, it has been
shown that CCN2 expression was increased in mesenchymal
stem cells (MSCs) and osteoblasts during formation of new
bone, suggesting its role in bone development,20 but its effect
when added to either human osteoprogenitor cells or osteo-
blasts has not been investigated yet. Furthermore, CCN2 is a
necessary mediator for the production of vascular basement
membranes,26 however, its effect on angiogenesis remains
unclear.27–30
HMGB1, unlike NELL-1 and CCN2, has never been used
as growth factor-based therapy, but knowledge about the
potency of this factor in the different processes involved in
bone repair makes it an attractive candidate. HMGB1 is a
chromatin protein mainly known due to its role as an alar-
min.31,32 Consequently, many studies showed that HMGB1 is
a potent proinflammatory cytokine secreted by monocytes
and macrophages able to regulate migration of mesangio-
blasts, smooth muscle cells, or myoblasts among others.33–36
Recently, it has been shown that HMGB1 has an osteomo-
dulatory action,37 being chemotactic to MSCs38 as well as
osteoblasts and osteoclasts during endochondral ossifica-
tion.31,39 Although HMGB1 is known to be able to upregulate
osteogenic markers when added to MSC culture in vitro,40 its
direct effect on osteoprogenitor and preosteoblast minerali-
zation has not been studied. In addition, various studies have
identified it as a putative proangiogenic factor and its over-
expression is related with an increased ability to develop
blood vessels.34,41,42
NELL-1, HMGB1, and CCN2 are indicated to play a role
in bone formation. However, their effect on major cell types
and specific processes involved in bone formation is barely
studied, and they were never directly compared. The main
goal of this study is to compare side by side NELL-1,
HMGB1, and CCN2 to BMP2 and assess whether they are
able to induce cell migration, osteogenic differentiation, and
neovascularization, indispensable processes needed for bone
formation. This was performed using cells from human origin:
two types of osteoprogenitors (human MSCs and fetal osteo-
blasts) and human umbilical vein endothelial cells (HUVECs).
Materials and Methods
Cell culture
Human MSCs were obtained from leftover material from
iliac crest biopsies of four donors (age 9–12 years; threemales
and one female) undergoing cleft palate reconstruction sur-
gery (Erasmus MC Ethics Committee number MEC-2014-
106) with implicit consent. Cells were seeded at a density of
50,000 cells/cm2 in a-MEM (Gibco, BRL), supplementedwith
10% fetal calf serum (FCS), 1 ng/mL fibroblast growth factor
(FGF2), 25mg/mL ascorbic acid-2-phosphate, 1.5mg/mL fun-
gizone, and 50mg/mL gentamicin. After 24 h, nonadherent
cells were washed out and adherent cells were expanded in the
abovementionedmedium. Themediumwas renewed twice per
week until MSCs neared confluency. Then, cells were used for
migration or osteogenic differentiation assays.
Simian virus-immortalized human fetal osteoblast (SV-HFO)
cells43 were expanded and cultured as previously described.44
HUVECs (Lonza) were cultured at a density of 5000
cells/cm2 in endothelial growth medium (EGM-2 with Sin-
gleQuots; Lonza). Medium was renewed every 2–3 days.
When cells neared confluency, they were used for migration
or tube formation assays.
Migration assay
MSC and HUVEC migration was assessed using modified
Boyden chambers (polyethylene terephthalate cell culture
inserts, pore size: 8 mm in diameter, Millipore-Merck).
Briefly, to analyze MSC migration, a-MEM containing
NELL-1 (0.07–3.5 nM [10–500 ng/mL], R&D Systems),
CCN2 (0.89–8.9 nM [10–100 ng/mL]; Abnova), HMGB1
(0.4–4 nM [10–100 ng/mL]; R&D Systems), and BMP2
(0.38–38 nM [10–1000 ng/mL]; kindly provided by Dr. Joa-
chim Nickel, Fraunhofer IGB) was added to the lower
chamber of a 24-well plate. Platelet-derived growth factor-
AB (PDGF-AB) (20 ng/mL) or 10% FCSwas used as positive
controls. 6 · 103 MSCs suspended in a volume of 200mL a-
MEM were added into the upper chamber. The plates were
incubated at 37C for 17 h. To test the chemotactic effect of
NELL-1 (10–500 ng/mL), CCN2 (10–100 ng/mL), HMGB1
(10–100 ng/mL), and BMP2 (10–1000 ng/mL) on HUVECs,
the endothelial cell basal medium (EBM-2, Lonza) containing
NELL-1, CCN2, HMGB1, or BMP2 was added in the lower
chamber. EGM-2 was used as positive control. 5 · 104 HU-
VECs were added into the upper chamber. The plates were
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incubated at 37C for 10 h. In both cases, the membrane was
then washed and the cells remaining on the upper surface of
the chambers weremechanically removedwith a cotton swab.
Those that had migrated to the lower surface were fixed with
4% formalin, stained with 4¢,6-diamidino-2-phenylindole
(DAPI) (100 ng/mL) in the dark for 5min, and imaged using
fluorescence microscopy (Zeiss Axiovert 200M Fluores-
cence Imaging) in five random fields for each membrane and
counted using ImageJ software.
Osteogenic differentiation
Osteogenic differentiation assays were performed on
MSCs and SV-HFOs. 3000 Cells/cm2 (MSCs) or 9000 cells/
cm2 (SV-HFOs) were seeded with a-MEM in a 12-well
plate. For MSCs, after 24 h, the medium was replaced with
the complete osteogenic medium: DMEM high glucose
(Gibco) with 10% FCS, 1.5 mg/mL fungizone, 50 mg/mL
gentamicin, 1 ng/mL FGF2, 25 mg/mL ascorbic acid-2-
phosphate, 10mM b-glycerophosphate, and 0.1 mM dexa-
methasone. For SV-HFOs, the osteogenic differentiation
medium consisted of phenol red-free a-MEM (Gibco), pH 7.5,
supplemented with 20mM HEPES (Sigma), streptavidin/
penicillin, 1.8mM CaCl2$2H2O (Sigma), 2% heat-inactivated
charcoal-treated FCS, 0.1mM dexamethasone, and 10mM b-
glycerophosphate. During each medium refreshment, medium
was supplemented with proteins of interest: NELL-1 (10–
500 ng/mL), CCN2 (10–100 ng/mL), HMGB1 (10–100 ng/
mL), and BMP2 (10–1000ng/mL). Osteogenic differentiation
was carried out until onset of mineralization, monitored by
measuring calcium concentration in the culture supernatant.
Cells were scraped from the culture dish in phosphate-buffered
saline (PBS)/0.1% Triton X-100. Cell lysates were sonicated
on ice before analysis.
DNA and protein measurements
For DNA measurement, cell lysates were incubated for
30min at 37C with 100mL heparin (8 IU/mL in PBS) and
50 mL RNAse A (50mg/mL in PBS) solution. Ethidium
bromide solution (25mg/mL) was added and DNA content
was measured on the Wallac 1420 Victor2 (PerkinElmer
Life and Analytical Science) plate reader using an excitation
filter of 340 nm and emission filter of 590 nm. For standards,
calf thymus DNA (Sigma) was used.
Protein was measured in cell lysates with BCA protein
assay (Pierce BCA protein assay; Thermo Scientific) ac-
cording to the manufacturer’s instructions.
Alkaline phosphatase activity
Alkaline phosphatase (ALP) activity was performed as
described previously45 by determining the release of para-
nitrophenol from paranitrophenyl phosphate (pNPP) in cell
lysates. pNPP (20mM) was added to each sample at 37C.
After exactly 10min, the reaction was stopped by adding
0.06M NaOH. Absorption was measured on the Wallac
1420 Victor2 plate reader at 405 nm. For standards, ALP
(10U/mL) from bovine kidney (Sigma) was used.
Mineralization
To quantify the calcium content, cell lysates were incu-
bated for 48 h in 0.24M HCl at 4C. For analysis of calcium
concentration in the culture medium, supernatant was col-
lected from day 9 onward. In both cases, the calcium content
was colorimetrically determined after addition of 1M eth-
anolamine buffer (pH 10.6), 19.8mM 8-hydroxyquinoline,
and 0.35mM O-cresolphthalein complexone, at 595 nm on
the Wallac 1420 Victor2.
For von Kossa staining, cell cultures were fixed for
15min in 4% formaldehyde, stained by 5% silver nitrate
solution (Sigma; 85228) for 30min under a 60 W light, and
imaged using an inverted microscope (Olympus CKX41).
HUVEC tube formation assay
Growth factor-reduced Matrigel (Corning) was added to a
96-well plate and incubated at 37C for 1 h. HUVECs were
resuspended in EBM supplemented with NELL-1, CCN2,
HMGB1, or BMP2. EGM-2 complete medium was used as
positive and EBM-2 as negative control. Fifteen thousand
cells were seeded on top of the Matrigel, incubated at 37C,
and imaged after 4, 6, and 24 h using an inverted microscope.
Three independent experiments in triplicate were performed.
The results were analyzed using ImageJ software.
Statistical analysis
Data were analyzed with IBM Statistics 21 (SPSS). A
linear mixed model was applied; the different conditions
(different doses of the proteins studied) were considered a
fixed parameter and the donors (experiments) as a random
factor. A descriptive analysis was performed to assess the
normal distribution of the data. When multiple comparisons
were analyzed, the Bonferroni test was performed. p < 0.05
was considered statistically significant.
Results
NELL-1, CCN2, and HMGB1 stimulated MSC
migration, whereas BMP2 did not
To determine whether the proteins could recruit progen-
itor cells to the site of injury, we assessed their effects on
migration of MSCs. The positive control PDGF-AB was
chemoattractant showing a 4.6-fold increase compared to
negative control (data not shown). NELL-1, CCN2,
HMGB1, but not BMP2, were capable of inducing MSC
migration (Fig. 1). NELL-1 increased migration 2-, 2.3-, and
2.79-fold compared to control in a dose-dependent manner,
although only statistically significant ( p< 0.05) with the
highest dose. CCN2 significantly increased migration at the
lowest and medium dose (2.75- and 2.48-fold, respectively),
while the highest dose had no effect compared to control. In
contrast, HMGB1 was chemotactic at the highest dose tes-
ted, 100 ng/mL, with more than fivefold increase compared
to control. Although there was a trend toward a stimulation
of migration of BMP2 on MSCs (1.3–1.6-fold increase), this
effect was not significant.
NELL-1, CCN2, HMGB1, and BMP2 proteins
stimulated EC migration
We explored the role of NELL-1, CCN2, HMGB1, and
BMP2 on HUVEC recruitment. The positive control (EGM-2
complete medium) showed a 3.2-fold increase in migration
compared to negative control (EBM). Interestingly, similar to
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MSCs NELL-1 and CCN2 stimulated HUVECs to migrate.
Specifically, NELL-1 increased migration in a dose-
dependent manner, showing more than twofold increase with
the highest dose, while CCN2 had a greater effect at the
lowest dose (more than twofold increase compared to con-
trol). Although HMGB1 showed less pronounced effect on
HUVEC than MSC migration, it had a significant effect on
migration in all the tested doses, showing a twofold increase
compared to the control. It is noteworthy that, in contrast to
the other three proteins that had similar effects on both cell
types with regard to dose, BMP2 showed different effects,
demonstrating a significantly higher EC migration at the
lowest and medium dose supplied with more than 1.5-fold
increase compared to control (Fig. 2).
BMP2 enhanced MSC osteogenic differentiation;
NELL-1, CCN2, and HMGB1 had no effect
Osteogenic differentiation of MSCs was assessed by
calcium deposition. Supplementation with NELL-1, CCN2,
or HMGB1 did not cause any increase or decrease in min-
eralization. However, when BMP2 was added, we observed
a dose-dependent stimulatory effect, with a significant in-
crease in nodule formation at the highest dose provided
(Fig. 3A). The results were corroborated quantitatively by
measuring the calcium content in the cell lysates, showing
that addition of BMP2 at the highest dose provided
(1000 ng/mL) had an almost twofold increase in minerali-
zation compared to the standard osteogenic differentiation
media (Fig. 3B).
BMP2 inhibited preosteoblast differentiation
and mineralization; NELL-1, CCN2, and HMGB1
had no effect
The addition of NELL-1, CCN2, and HMGB1 did not
increase mineralization or ALP activity at either of the time
points studied (Fig. 4A). Interestingly, and in contrast to the
effect observed with hMSCs, the addition of BMP2 to the
preosteoblast culture had a direct inhibitory effect on dif-
ferentiation and mineralization. The decrease in ALP ac-
tivity became significant at day 16. In addition, a reduction
in the ECM calcium content at the lowest dose provided was
detected (Fig. 4A, B). However, when the highest dose was
provided (1mg/mL), the inhibitory effect was no longer
observed and the mineralization reached control levels.
NELL-1, CCN2, HMGB1, and BMP2 stimulated
neovascularization
We have determined the capability of the factors to pro-
mote formation of tubular-like structures by ECs in vitro.
There was a significant improvement in tube formation at
the medium dose of NELL-1 added (100 ng/mL), Further-
more, CCN2 and HMGB1 were able to enhance tube for-
mation at the lowest doses supplied. BMP2 also enhanced
tube formation in a dose-dependent manner, resulting in a
FIG. 1. NELL-1, CCN2, and HMGB1 stimulated MSC migration. Average migration of MSCs exposed to several doses
of each factor relative to the negative control (n = 4 donors in duplicate). The bars represent the mean – SD. BMP2, bone
morphogenetic protein 2; CCN2, connective tissue growth factor; HMGB1, high mobility group box 1; MSCs, mesen-
chymal stem cells; NELL-1, nel-like molecule type 1.
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significant effect on tube formation when the highest dose
was added (Fig. 5B).
Discussion
We directly compared four proteins that are acknowl-
edged for their apparent ability to stimulate osteogenesis
in vitro or in vivo.20,31,46,47 This is the first study to directly
compare these proteins for their ability to induce recruit-
ment, osteogenic differentiation, and neovascularization
using human cells. Our results demonstrate the ability of
NELL-1, CCN2, and HMGB1 to attract both MSCs and ECs
even at low doses compared to BMP2. Since new blood
vessel formation is crucial for bone development, we as-
sessed neovascularization in an in vitro model, demon-
strating that all four tested proteins were able to stimulate
formation of tube-like structures. Interestingly, in contrast to
BMP2, NELL-1, CCN2, and HMGB1 did not significantly
increase the osteogenic differentiation capacity of MSCs
above that induced by dexamethasone. Also of note, we
observed that BMP2 negatively impacted preosteoblast
mineralization, whereas the others had no effect.
Effects on cell migration
It is generally thought that BMPs are mediators of os-
teoprogenitor cell recruitment. However, it had been pub-
lished that BMP2 had no effect in the recruitment of MSCs,
neither in the cultured MSCs nor in the marrow ablation
tissues.48 In our study, we did not see any increase in MSC
migration by BMP2 either. The BMP2 chemotactic effect
seems to vary between EC subtypes; studies performed with
ECs showed that BMP2 was not able to stimulate human
aortic EC migration,6 but it stimulated HUVEC migration.49
Our data confirmed that BMP2 is able to stimulate migra-
tion of HUVEC when doses between 10 and 100 ng/mL are
supplied.
Where BMP2 had no effect on MSC migration and less
than doubled the migration of HUVEC, we observed up to a
threefold increase in MSC and HUVEC migration when
HMGB1, CCN2, or NELL-1 was added to the culture.
HMGB1, as a signal of tissue damage, is known to be capable
of inducing migration in many different cell types, including
inflammatory cells.36,50,51 Fewer articles exist investigating
the effects of HMGB1 on osteogenic cells, but those that do
indicate it to be important in cell recruitment. Meng et al.
demonstrated that HMGB1 promotes MSC migration up to
2.5-fold compared to control.38 Our results confirm these
findings, showing that HMGB1 has a highly significant che-
motactic effect on MSCs above doses of 50 ng/mL. To date,
there is very little reported about HMGB1s chemotaxis on
primary ECs. Low doses of HMGB1 are able to promote
endothelial progenitor cell migration using transwells coated
with fibronectin or fibrinogen.52 Bauer et al. have performed a
wound healing migration assay and have shown that 1mg/mL
of HMGB1 is able to induce migration of HUVEC.53 We
show that HMGB1 is highly chemoattractant to HUVECs,
and even a hundred times lower concentration than 1mg/mL
is sufficient to induce more than a twofold increase compared
FIG. 2. NELL-1, CCN2, HMGB1, and BMP2 stimulated EC migration. Average migration of HUVECs exposed to
several doses of each factor relative to the negative control (n = 3 donors in duplicate). The bars represent the mean – SD.
HUVECs, human umbilical vein endothelial cells.
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FIG. 3. Effect of NELL-1, CCN2, HMGB1, and BMP2 on the MSC mineralization. Human MSCs were induced to
mineralize in the absence or continuous presence of NELL-1, CCN2, HMGB1, or BMP2. (A) Von Kossa staining of nodule
formation at the onset of mineralization. Pictures were taken at 4· magnification. (B) Quantification of calcium deposition
(nmol/cm2) in the ECM at the onset of mineralization relative to control (osteogenic differentiation medium). n = 3 donors in
triplicate. The bars represent the mean – SD. ECM, extracellular matrix.
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FIG. 4. Effect of NELL-1, CCN, HMGB1, and BMP2 on the osteoblast differentiation measured by ALP activity and
mineralization. (A) ALP activity (mU/cm2) during Simian virus-immortalized human fetal osteoblast culture in osteogenic
differentiation medium (control) and after continuous addition of the tested proteins at day 9 (gray bars) and 16 (black bars) of
culture. Results are shown relative to day 9 control. (B) Quantification of calcium deposition (nmol/cm2) in the ECM at day 16.
Values are expressed as fold change compared to osteogenic medium without additional proteins. Results are shown relative to
control in both graphs (n= 3 experiments performed in triplicate). The bars show the mean–SD. ALP, alkaline phosphatase.
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FIG. 5. Effect of NELL-1, CCN2, HMGB1, and BMP2 HUVEC on tube formation on Matrigel. (A) Representative
picture of tube-like structures formed by HUVEC after 6 h of treatment with vehicle control, 10 ng/mL HMGB1, 50 ng/mL
HMGB1, and 100 ng/mL HMGB1. Pictures were taken with 1.5· magnification. (B) Quantification of tube formation, and
total number of nodes analyzed. The bars show the mean with SD.
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to control. In addition, from 10 to 100 ng/mL, we observed a
similar chemoattractant effect, suggesting a low dose is suf-
ficient to stimulate EC migration.
CCN2 has been shown to promote migration of human
MSCs and human dermal microvascular ECs when trans-
fected with pCCN2.24,25 Nonetheless, the effect of the ad-
dition of the protein CCN2 to MSCs or ECs had not been
studied before. We demonstrated that the addition of low
dose (10 ng/mL = 0.89 nM) of CCN2 to the media is suffi-
cient to obtain a significant migratory response from MSCs
and HUVECs, reaching more than a fourfold increase
compared to the control. The fact that CCN2 showed an
inverse dose response is potentially interesting for endoge-
nous cell recruitment though slow release systems.
NELL-1 has been shown to inhibit renal carcinoma cell
migration and adhesion.54 However, we did not find pub-
lished data about the effect of NELL-1 on MSC and EC
migration. We demonstrated in this study its ability to
promote migration of both cell types. In fact, it was able to
promote EC migration at lower doses than BMP2 (BMP2,
100 ng/mL = 3.8 nM; NELL-1, 100 ng/mL = 0.7 nM) and
MSC migration when BMP2 did not.
Effects on osteogenesis
BMP2 is the best known osteogenic factor. Next to the
capacity to induce bone formation in vivo, the capacity of
BMP2 to induce osteogenic differentiation of MSCs in vitro
has already been tested.55,56 Our data confirm this as we
observed an almost twofold increase when 1 mg/mL of
BMP2 was added to the culture. However, little is known
about its effect on osteoblasts. In this study, we observed an
inhibition of mineralization when BMP2 was added to oste-
oblast cultures in a concentration range of 10–100ng/mL.
Interestingly, we did not observe that inhibitory effect when
the highest dose was added (1mg/mL). This could be due to
the fact that SV-HFOs express activin,57 which may interfere
with BMP2 or simply because BMP2 is not an essential
stimulus when the cells are already committed to the osteo-
genic pathway. Many studies indicated HMGB1’s role in the
induction of endochondral ossification in vivo and that it
may act as a bone resorption signal.31 However, HMGB1 has
not been used as a therapeutic agent for bone regeneration
and whether it has any effect on either osteoprogenitor or
osteoblast differentiation and mineralization is barely
studied. We did not observe any effect on osteogenic dif-
ferentiation when HMGB1 was added to the MSC or pre-
osteoblast culture media. Although it has been shown that
CCN2 expression is increased in MSCs and osteoblasts
during bone formation,20 the effect of the addition of the
protein CCN2 to MSCs or to osteoblasts had not been
examined previously. Our study demonstrates that while it
promotes migration of osteoprogenitor cells, CCN2 is not
able to increase osteogenesis in contrast to a published
study by Safadi et al.,58 who used rat primary osteoblasts
and showed an increase on calcium deposition when
100 ng/mL of CCN2 was added to the culture beginning at
day 11. We cannot exclude that the differences in experi-
mental setup, including addition of dexamethasone and
single dosing of CCN2, might explain the results.
With regard to NELL-1, most of the osteogenic differ-
entiation studies have been performed with either human
osteosarcoma cell lines or murine osteoblast-like cells.59–61
These studies have shown that, when transfected with NELL-
1, these cells increase late osteogenic differentiation markers
and ECM mineralization. Recently, Pang et al. have identi-
fied a functional transcript of NELL-1 able to induce osteo-
genic differentiation of a murine MSC line.62 However, no
information on human MSCs or osteoblasts was available.
We observed an osteogenic trend when NELL-1 was added at
low doses to preosteoblasts, although with high variability
between cultures. Even then, comparison on a molar basis
suggests that NELL-1 could have an osteogenic inducing
effect even at low doses, in contrast to BMP2 that exhibited
the reverse effect. Although we did not observe a significant
effect of NELL-1 on osteogenic differentiation, a synergistic
effect of NELL-1 and BMP2 has been shown on osteogenesis
in vitro.63 Moreover, NELL-1 can suppress BMP2-induced
inflammation and enhance BMP2-induced bone formation
in vivo.64–66 Therefore, NELL-1 is a potentially interesting
candidate to be used alone or with BMP2. NELL-1 and
BMP2 might stimulate different stages of osteogenic dif-
ferentiation; where NELL-1 stimulates osteoprogenitor cell
migration and could enhance preosteoblast differentiation,
BMP2 might promote differentiation of skeletal stem cells.
Effects on vascularization
BMP2 had been shown to stimulate angiogenesis in de-
veloping tumors.6,67 In bone tissue engineering, however,
BMP2 is frequently used in combination with angiogenic
factors as vascular endothelial growth factor (VEGF) or
angiopoietin 1,68–70 suggesting BMP2 does not optimally
induce vascularization. In this study, we demonstrated the
ability of BMP2 to induce the formation of tube-like
structures at a dose of 1 mg/mL, a relatively much higher
dose than required for CCN2, HMGB1, or NELL-1.
HMGB1 is known to have diverse roles in angiogenesis
during disease and tissue repair42 and has been suggested to
induce angiogenesis through a VEGF-dependent mecha-
nism.71 HMGB1 was shown to induce tube formation by
microvascular ECs at doses ranging from 0.1 to 1 mg/
mL.72,73 In this study, we show that much lower doses of
HMGB1 are sufficient to recruit ECs and to promote tube
formation. CCN2 has been shown to act as a proangiogenic
factor, coordinating vasculature formation during skeletal
development21,74 and also as an antiangiogenic agent in-
hibiting VEGF-induced angiogenesis,29 suggesting that
CCN2 regulates angiogenesis through direct and indirect
mechanisms.75 We show that CCN2 has proangiogenic
properties when it is added directly to ECs, even at much
lower doses than are required for BMP2 to induce a similar
effect. Therefore, CCN2 might also be an interesting factor
to be combined in future studies with a powerful os-
teoinductive growth factor, due to its chemotactic and an-
giogenic features. Although some studies have shown that
NELL-1 induces VEGF expression in human pericytes and
perivascular stem cells,12,76 to our knowledge, there are no
previous publications investigating the effects of NELL-1
on vascularization of ECs. We demonstrate that the addition
of NELL-1 positively affects EC migration within a tight
dose range, producing a significant increase at 100 ng/mL, a
larger dose than needed with either HMGB1 or CCN2, but
still 10 times lower than needed with BMP2.
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Bone defect repair
To accelerate and optimize bone remodeling, using more
than one type of growth factor involved in bone formation
could be preferable to reduce possible side effects due to
high doses used when single-factor therapies are applied. In
addition, several studies have shown that not only the dose
but also the timing of release of the proteins from the carrier
used for bone formation greatly modifies the outcome.77
Based on the promising properties of NELL-1, HMGB1,
CCN2, and BMP2 with regard to their promotion of bone
formation-related processes, in vivo analyses using dual
release systems should be performed to assess their potency
for bone defect repair.
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